RxDoctor Payments DataLook up a doctor →

Luay Sayed, MD

Interventional Cardiology · Shelby Township, MINPI 1063414696

Payments from drug & device makers

$29,439in general payments, 2019–2025

Across 565 payments — averaging $52.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$7K
  • Abiomed$5K
  • Boston Scientific$3K
  • Shockwave Medical, Inc$2K
  • Edwards Lifesciences$2K
  • Abbott$2K
  • plus $8K from 43 others
$135in research payments, 2019–2025

Across 1 payment — averaging $134.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$135

What the payments were for

  • Consulting fees$8,65629%
  • Speaking & faculty fees$3,00010%
  • Travel & lodging$5,84720%
  • Food & beverage$11,87740%
  • Education$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,439 in reported general payments places this provider in the 65th percentile of 187 interventional cardiology providers in Michigan.

See all interventional cardiology providers in Michigan

Medicare billing

Part B allowed, 2024
$752,711
Medicare patients
1,711
Services billed
7,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$441,469
XareltoRivaroxaban338$424,176
EntrestoSacubitril/Valsartan127$179,635
Repatha SureclickEvolocumab212$155,560
JardianceEmpagliflozin30$38,668
BrilintaTicagrelor36$32,631
Metoprolol Succinate1,028$18,826
Praluent PenAlirocumab17$15,438
Ranolazine ErRanolazine142$12,692
FarxigaDapagliflozin Propanediol13$11,422
ClopidogrelClopidogrel Bisulfate523$9,431
Atorvastatin Calcium663$9,263
Losartan Potassium505$6,670
Amiodarone Hcl206$6,600
Rosuvastatin Calcium333$6,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$312$441,469353 claims
Johnson & JohnsonXarelto$878$424,176338 claims
NovartisEntresto$840$179,635127 claims
AstraZenecaBrilinta, Farxiga$424$44,05349 claims
Arbor Pharmaceuticals, Inc.Edarbi$40$3,04712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 interventional cardiology providers in Michigan.

Other interventional cardiology in Shelby Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →